Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab versus placebo in Chinese participants at risk of cognitive and functional decline due to preclinical Alzheimer's disease
CTR20261290Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of donanemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Jul 2026; status: active.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20261290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261290.